February 24th, 2023

Philanthropic Partnership Sets sights on Sustainable Improvements to Health Care

Making health care more sustainable for generations to come is the goal behind a ground-breaking new public-private partnership between Vancouver Coastal Health (VCH), Boehringer Ingelheim Canada Ltd. and VGH & UBC Hospital Foundation. This unique partnership focuses on funding innovation initiatives in the areas of planetary health, Indigenous health and chronic disease, as these are shared priorities for the organizations...READ MORE

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announce that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 (“N,N-Dimethyltryptamine or DMT”). AGN Neuro plans to be the first company globally to investigate DMT for TBI in humans and is planning to begin a Phase 2 clinical trial in Q4, 2023...READ MORE

Gene Biomedical – Saliva Multi-drug 7 Panels Test Device

The Saliva Multi-drug 7 Panels Test Device is a rapid visual immunoassay for detecting drug abuse in human oral fluid specimens. The product has gained strategic procurement cooperation with several countries, including Vietnam, Laos, the UK, and Dubai, and the company aims to expand its market reach in Southeast Asian countries...READ MORE

Life Diagnostics Partners with Omega Laboratories to Open a New Laboratory in UAE

Omega Laboratories, a leading provider of laboratory testing solutions, is proud to announce a new partnership with Life Diagnostics to open state-of-the-art drugs of abuse testing laboratory in the United Arab Emirates (UAE). The new laboratory will bring drugs of abuse testing to the MENA region. The laboratory will incorporate Omega’s years of toxicology experience and its IT solutions, with the leading industry expertise of Life Diagnostics “Life Dx.”, UAE’s fastest-growing diagnostics services provider....READ MORE

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced that it has expanded its clinical research capabilities into Arizona. The site, located in Phoenix where Numinus operates mental health clinics, is Numinus’ third clinical trial research site in the US, and fifth research site overall. It will offer clinical research management services, focused on advancing psychedelic science through Cedar Clinical Research (CCR)...READ MORE

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced financial results for the second quarter of fiscal year 2023 which ended December 31, 2022. Highlights include:

• Closed calendar year 2022 with strong cash position of $11.5 million
• Approaches completion of enrollment for Ph 2 clinical trial in EB
• Advances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s...READ MORE

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N Dimethyltryptamine” or “DMT”), a known psychedelic compound that is part of the tryptamine family. AGN Neuro also reports that the safety review committee has approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues...READ MORE

Call for Nominations: 2023 Catalyst Award for Top New Hire

BioTalent Canada is now accepting nominations for its industry-leading Catalyst Award for Top New Hire. The coveted award recognizes the achievements of young employees who are wage subsidy recipients in Canada’s burgeoning bio-economy. The award also spotlights employers that give these young minds an opportunity to grow and thrive. Since the award was launch in 2015, the Catalyst Award for Top New Hire has shone a light on the positive impact students, new graduates, barriered youth, and Internationally Educated Professionals have when employers give them the opportunity to put their education and skills into practice...READ MORE

Salix Announces 2023 Gastrointestinal Health Scholars Program

Bausch Health Companies Inc. announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.

• Undergraduate Scholar Awards for students pursuing undergraduate degrees
• Graduate Scholar Awards for students pursuing graduate degrees
• Working Parent’s Scholar Award for students who are parents pursuing undergraduate, vocational/technical or graduate degrees
• Single Parent’s Scholar Award for students who are single parents pursuing undergraduate, vocational/technical or graduate degrees...READ MORE

B.C. Launches Action Plan to Better Detect, Treat, Prevent Cancers

Cancer patients and their loved ones will benefit from expanded access to care as B.C. launches a new action plan with immediate steps to better prevent, detect and treat cancers, delivering improved care for people now while preparing for the growing needs of the future. An initial $440-million investment will expand cancer-care teams and service hours, introduce revised pay structures to ensure B.C. is attractive and competitive for oncologists and cancer-care professionals, improve cancer screening programs, support cancer research, increase Indigenous patient support positions, and support patients who must travel for care from rural communities...READ MORE

Government of Canada Releases Interim Sustainable Jobs Plan to Enable the Creation of Good, Middle Class Jobs Across Canada

A net-zero emissions economy represents significant opportunities for Canadians – to secure and create jobs, to grow our industries, and to lead the world with the resources and technologies it will need for generations to come. With highly skilled and dedicated workers, abundant natural resources and energy sources critical for a net-zero future, and a thriving clean technology industry, Canada is uniquely positioned to seize the moment...READ MORE

Health Minister Jean-Yves Duclos Tables the 2021-22 Canada Health Act Annual Report in Parliament

Universal, accessible, and publicly funded health care is a point of pride for Canadians, which is why upholding the Canada Health Act (CHA) remains critical to protecting our health care system. The Honourable Jean-Yves Duclos, Minister of Health, tabled the 2021-2022 Canada Health Act Annual Report in Parliament. This tabling follows the recent announcement of the federal government’s plan to invest $198.6 billion over 10 years, including $48.7 billion in new funding, to improve health care services for Canadians...READ MORE

BCIT Names Dr. Jeff Zabudsky as Next President

Dr. Zabudsky’s appointment is the result of an extensive and competitive search following the retirement of former President Kathy Kinloch in July 2022. Dr. Zabudsky joins BCIT at a pivotal time in the Institute’s growth – with extensive capital projects currently underway including the BCIT Tall Timber Student Housing Project and the $162.6 million Trades and Technology Complex at the Burnaby Campus...READ MORE

FDA to Require Diversity Plan for Clinical Trials

The US Food and Drug Administration (FDA) will soon require researchers and companies seeking approval for late-stage clinical trials to submit a plan for ensuring diversity among trial participants. Many scientists have applauded the move, which was laid out in a spending bill signed into law by US President Joe Biden in December 2022. They say that broadening participant pools is important to make medicines more effective across the whole population. But they are not yet convinced that the FDA will adequately enforce the new requirement...READ MORE

Government Releases Blueprint for Canada Innovation Corporation

In creating the CIC, the government is following through on its Budget 2022 commitment to establish an innovation agency to drive Canadian business investment in research and development (R&D) and foster economic growth. The CIC will operate with an initial budget of $2.6 billion over four years, and is expected to begin its operations in 2023....READ MORE

Clinical Trials Administrator

Eupraxia Pharmaceuticals is seeking a Clinical Trials Administrator (CTA). The clinical trials administrator primarily manages the administrative aspects of a number of clinical trials, at every stage of the process. This is an opportunity to work in a small, entrepreneurial and highly motivating environment, with a strong emphasis on work/life balance and a supportive company culture. We offer a competitive salary, excellent benefits and career development opportunities.

 LEARN MORE

Manager, Investor Relations / Corporate Communications

The role of the Manager, Investor relations / Corporate Communications will initially be to support corporate activities related to Investor Relations, Communications and Business Development. Key stakeholders include financial regulators, shareholders, bankers and analysts, potential partners and employees. The position works closely with the CEO and Executive team and maintains a broad perspective on the business and all key developments within the company, ensuring the effective communication to appropriate constituents.

LEARN MORE

Senior Lab Manager

STEMCELL Technologies is seeking a Senior Lab Manager. The role holder will be required to facilitate lab build outs for space planning, procure lab supplies, maintain and certify equipment, and budget management. The Senior Lab Manager will be accountable for the Lab Ops portfolio including SOPs, KPIs, EH&S compliance, lab safety standards, and lab skills training curriculums. The Senior Manager works collaboratively with internal stakeholders and external suppliers to deliver safe, scalable, and high performing lab operations facilities.

LEARN MORE

Rudra was founded in 2022 by three scientists who are entrepreneurs at heart and collectively have more than five decades of experience spanning the pharma, biotech, nutraceutical, cannabis and other emerging industries.

Rudra provides services in the fields of Consulting, Learning & Development, and Innovation & IP Development. Their specialties include pharmaceutical, biotechnology, medical cannabis, analytical development, medical device, and more.

Rudra, which means, Eradicating problems at the root, is their inspiration and mission.

Visit Website

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Our focus is on advancing the care of patients through its research and development efforts directly impacts our relationships with physicians, patients and their caregivers, and our employees.

Visit Website